{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidfkxp4bjqlefhr2imov4xqdl56453veelmbs4drbaeznwmaypz54",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mk7fttaew5d2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibwwgofeyyqdc44tzifqzuin7nvnakwbv2u5pxvkq6tpsv6wpeeqm"
    },
    "mimeType": "image/png",
    "size": 2363067
  },
  "path": "/news/2026-04-flag-based-regimen-strong-outcomes.html",
  "publishedAt": "2026-04-23T20:40:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement.",
  "title": "FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia"
}